ESTRO 2025 - Abstract Book

S1691

Clinical - Sarcoma & skin cancer & malignant melanoma

ESTRO 2025

Twelve patients remain alive, while 17 have died, primarily from disease progression.

Conclusion: MFS presents complex challenges, requiring a multidisciplinary approach for optimal management. Surgery with wide margins remains the cornerstone of treatment, while RT is associated with improved local control and reduced recurrence. Outcomes are notably better at sarcoma reference centers with multidisciplinary tumor boards, emphasizing the importance of specialized care for these patients.

Keywords: myxofibrosarcoma, surgery, radiotherapy

References: 1. Chen, Wenlin, et al. "Analysis of clinical factors impacting recurrence in myxofibrosarcoma." Scientific Reports 14.1 (2024): 3903.

2574

Mini-Oral A Retrospective Outcome Study for Proton Beam Therapy in Ewing's Sarcoma: The First UK experience. Shweta Sharma 1 , Khalid Mohamed Abutaleb 1 , Shermaine Pan 1 , Nicky Thorp 1 , Abiola Fatimilehi 1 , James Wylie 1 , Hanis Hanafi 1 , Jeremy Khong 1 , Elaine Quinlan 1 , Jasima Latif 1 , Ahitagni Biswas 1 , Matthew Lowe 1 , Yuwei Wang 2 , Simeon Aguedu 2 , Jason Kennedy 2 , Sarah Jones 2 , Katie Heslin 2 , Mark Reed 1 , Martha Humphrey 1 , Ed Smith 1 1 Proton Beam Therapy Centre, The Christie NHS Foundation Trust, Manchester, United Kingdom. 2 Proton Clinical Outcomes Unit, The Christie Proton Beam Centre, Manchester, United Kingdom Purpose/Objective: Ewing’s Sarcoma (ES) is the second most common bone tumour of children and young adults 1 . Most patients are treated with a multimodality approach combining chemotherapy with local treatment comprising surgery, radiotherapy or both 2 . The choice of local therapy is variable and there is no clear evidence to guide the optimal approach 3 . We present a single institution outcomes of ES patients who have received proton therapy.